119 related articles for article (PubMed ID: 38669067)
1. Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.
Nief CA; Hammer PM; Wang A; Charu V; Tanweer A; Litkouhi B; Kidd E; Gentles AJ; Howitt BE
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38669067
[TBL] [Abstract][Full Text] [Related]
2. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.
Yang JY; Werner HM; Li J; Westin SN; Lu Y; Halle MK; Trovik J; Salvesen HB; Mills GB; Liang H
Clin Cancer Res; 2016 Jan; 22(2):513-23. PubMed ID: 26224872
[TBL] [Abstract][Full Text] [Related]
3. Pilot Study to Establish a Novel Five-Gene Biomarker Panel for Predicting Lymph Node Metastasis in Patients With Early Stage Endometrial Cancer.
Huang CY; Liao KW; Chou CH; Shrestha S; Yang CD; Chiew MY; Huang HT; Hong HC; Huang SH; Chang TH; Huang HD
Front Oncol; 2019; 9():1508. PubMed ID: 32039004
[No Abstract] [Full Text] [Related]
4. ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.
Gonzalez-Bosquet J; Weroha SJ; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Yadav S; Couch FJ; Podratz KC
PLoS One; 2022; 17(12):e0278408. PubMed ID: 36454788
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
Han KH; Kim HS; Lee M; Chung HH; Song YS
Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
[TBL] [Abstract][Full Text] [Related]
6. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas.
Jamieson A; Vermij L; Kramer CJH; Jobsen JJ; Jürgemlienk-Schulz I; Lutgens L; Mens JW; Haverkort MAD; Slot A; Nout RA; Oosting J; Carlson J; Howitt BE; Ip PPC; Lax SF; McCluggage WG; Singh N; McAlpine JN; Creutzberg CL; Horeweg N; Gilks CB; Bosse T
Clin Cancer Res; 2023 Dec; 29(23):4949-4957. PubMed ID: 37773079
[TBL] [Abstract][Full Text] [Related]
7. A long noncoding RNAs signature to improve survival prediction in endometrioid endometrial cancer.
Xu Q; Yang Q; Zhou Y; Yang B; Jiang R; Ai Z; Teng Y
J Cell Biochem; 2019 May; 120(5):8300-8310. PubMed ID: 30548294
[TBL] [Abstract][Full Text] [Related]
8. Validation of ultrasound strategies to assess tumor extension and to predict high-risk endometrial cancer in women from the prospective IETA (International Endometrial Tumor Analysis)-4 cohort.
Verbakel JY; Mascilini F; Wynants L; Fischerova D; Testa AC; Franchi D; Frühauf F; Cibula D; Lindqvist PG; Fruscio R; Haak LA; Opolskiene G; Alcazar JL; Mais V; Carlson JW; Sladkevicius P; Timmerman D; Valentin L; Bosch TVD; Epstein E
Ultrasound Obstet Gynecol; 2020 Jan; 55(1):115-124. PubMed ID: 31225683
[TBL] [Abstract][Full Text] [Related]
9. The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma.
Gong S; Quan Q; Meng Y; Wu J; Yang S; Hu J; Mu X
Heliyon; 2023 Jul; 9(7):e18016. PubMed ID: 37519747
[TBL] [Abstract][Full Text] [Related]
10. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic Evaluation and Molecular Profiling of Recurrent Stage IA Endometrial Endometrioid Carcinoma: A Case-control Study.
Sharma AE; Moran A; Somasegar S; Steinhardt G; Chapel DB; Lastra RR; Lee NK; Ritterhouse LL; Bennett JA
Int J Gynecol Pathol; 2023 Jan; 42(1):26-34. PubMed ID: 35125405
[TBL] [Abstract][Full Text] [Related]
12. Why do some patients with stage 1A and 1B endometrial endometrioid carcinoma experience recurrence? A retrospective study in search of prognostic factors.
Ocak B; Sahin AB; Oz Atalay F; Ozsen M; Dakiki B; Ture S; Sali S; Tanriverdi O; Bayrak M; Ozan H; Demiroz Abakay C; Deligonul A; Cubukcu E; Evrensel T
Ginekol Pol; 2021 Jun; ():. PubMed ID: 34105738
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
[TBL] [Abstract][Full Text] [Related]
14. Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer.
Long KC; Zhou Q; Hensley ML; Alektiar KM; Gomez J; Gardner GJ; Chi DS; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2012 Apr; 125(1):99-102. PubMed ID: 22112609
[TBL] [Abstract][Full Text] [Related]
15. Predicting high-risk endometrioid carcinomas using proteins.
Du D; Ma W; Yates MS; Chen T; Lu KH; Lu Y; Weinstein JN; Broaddus RR; Mills GB; Liu Y
Oncotarget; 2018 Apr; 9(28):19704-19715. PubMed ID: 29731976
[TBL] [Abstract][Full Text] [Related]
16. Genomic Determinants of Early Recurrences in Low-Stage, Low-Grade Endometrioid Endometrial Carcinoma.
Safdar NS; Stasenko M; Selenica P; Martin AS; da Silva EM; Sebastiao APM; Krystel-Whittemore M; Abu-Rustum NR; Reis-Filho JS; Soslow RA; Shen R; Mueller JJ; Oliva E; Weigelt B
J Natl Cancer Inst; 2022 Nov; 114(11):1545-1548. PubMed ID: 35699480
[TBL] [Abstract][Full Text] [Related]
17. Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
Zhu M; Jia N; Huang F; Liu X; Zhao Y; Tao X; Jiang W; Li Q; Feng W
BMC Cancer; 2017 Oct; 17(1):696. PubMed ID: 29061125
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ
Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754
[TBL] [Abstract][Full Text] [Related]
19. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
Raffone A; Catena U; Travaglino A; Masciullo V; Spadola S; Della Corte L; Piermattei A; Insabato L; Zannoni GF; Scambia G; Zullo F; Bifulco G; Fanfani F; Di Spiezio Sardo A
Gynecol Oncol; 2021 Jun; 161(3):795-801. PubMed ID: 33812697
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
[Next] [New Search]
